Please login to the form below

Not currently logged in
Email:
Password:

Neon Therapeutics taps Dr Richard Gaynor for R&D leadership role

He recently retired from Lilly after more than 15 years with the firm

Neon Therapeutics Richard GaynorNeon Therapeutics has appointed Dr Richard Gaynor as president of research and development to succeed its interim chief scientific office Robert Tepper, who will continue to sit on the firm's board.

Dr Gaynor recently retired from Lilly's oncology division, where he was spent more than 15 years, most recently as senior vice president of global product development and medical affairs.

At Cambridge, US-based Neon he will be tasked with guiding the immuno-oncology company's research programmes, which are focused on developing neoantigen-based therapeutic vaccines and T cell therapies.

Hugh O'Dowd, chief executive officer of Neon Therapeutics said the company was privileged to have Dr Gaynor join its team.

“Richard brings an enormous depth of oncology experience, having overseen many innovative drugs through early research into clinical development and commercialisation. His knowledge and leadership reinforces Neon Therapeutics' leadership in neoantigen-based immuno-oncology treatments.”

Dr Gaynor began his career in academia before joining Lilly in 2002 to oversee both oncology drug discovery and early clinical development.

12th December 2016

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics